A Study of Two Doses of LAsMiditan (100 mg and 200 mg) Compared to Placebo in the AcUte Treatment of MigRAIne: A Randomized, Double-blind, Placebo-controlled Parallel Group Study

Trial Profile

A Study of Two Doses of LAsMiditan (100 mg and 200 mg) Compared to Placebo in the AcUte Treatment of MigRAIne: A Randomized, Double-blind, Placebo-controlled Parallel Group Study

Completed
Phase of Trial: Phase III

Latest Information Update: 04 Aug 2017

At a glance

  • Drugs Lasmiditan (Primary)
  • Indications Migraine
  • Focus Registrational; Therapeutic Use
  • Acronyms SAMURAI
  • Sponsors CoLucid Pharmaceuticals
  • Most Recent Events

    • 04 Aug 2017 According to an Eli LiIlly media release, results from this trial were presented at the American Headache Society (AHS) annual meeting in June 2017.
    • 05 Oct 2016 Results of onset of action analysis published in a CoLucid Pharmaceuticals media release.
    • 17 Sep 2016 According to a CoLucid Pharmaceuticals media release, results from this study were presented at a symposium during the 5th European Headache and Migraine Trust International Congress (EHMTIC 2016).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top